|
|
Article: New Delhi, Oct 19 (PTI) Pharma major Ranbaxy laboratories Ltd has announced the successful completion of the Proof of Concept (POC) Phase II studies of its anti-malarial molecule, RBx 11160.
- Article from:
- PTI - The Press Trust of India Ltd.
- Article date:
- October 19, 2005
CopyrightCOPYRIGHT 2005 Asia Pulse Pty Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The molecule, jointly developed by the company and Medicines of Malaria Venture in Geneva, was found to be safe and effective in reducing malaria parasite count, the company informed the Bomaby Stock Exchange today.
"Progress on RBx 1160, which is emerging as a potential anti-malarial New Chemical Entity candidate, will ...
Related newspaper, magazine, and journal articles:
|